Multibagger Stock: Granules India Ltd.
Multibagger Stock
Granules India is a prominent manufacturer of Active Pharma Ingredients (APIs), Intermediates, and Finished Dosages, which includes medicines, on a large scale.
The company has achieved significant success in its revenue generation, with five key products contributing to 85 percent of its FY2023 revenue. These products are Paracetamol, Ibuprofen, Metformin, Methocarbamol, and Guaifenesin.
In the current market scenario, Granules India’s shares closed on a negative note due to weak market sentiment.
However, the long-term investment in the company has proven to be highly profitable, making the investor a millionaire with an initial investment of Rs 75,000.
This success has attracted the attention of brokerage firms, who anticipate further growth for Granules India.
ICICI Securities, a brokerage firm, predicts that Granules India’s shares have the potential to increase by approximately 25 percent from their current level.
The company’s shares closed at Rs 287.05 (Granules India Share Price) on the BSE, registering a marginal decline of 0.17 percent.
Overall, despite the short-term market fluctuations, Granules India’s long-term prospects are viewed favorably, and the company is expected to continue its growth trajectory.
Granules India’s Remarkable Stock Performance Creates Millionaires
Granules India has been instrumental in creating millionaires through its remarkable stock performance. On December 20, 2002, the company’s shares were valued at just Rs 2.15.
Fast forward to the present, the shares are priced at Rs 287.05, reflecting an astounding gain of 13,251 percent over a span of 21 years.
This substantial increase in share value has enabled investors to become millionaires, with an initial investment of only Rs 75,000.
Examining the movement of Granules India’s shares in the past year, on June 23, 2022, the stock reached its lowest point in the year, trading at Rs 238.05.
However, the subsequent months witnessed an upswing in share purchases, resulting in a significant surge of more than 60 percent within just five months.
This surge pushed the stock to its 52-week high of Rs 381.25 on November 4, 2022. At this peak, the stock’s rally came to a halt, and it has since experienced a decline of approximately 25 percent from its highest point.
What’s the Next Trend for Granules India?
Granules India, a leading manufacturer of APIs, Intermediates, and Finished Dosages, operates on a large scale with seven plants.
The company is actively engaged in both B2B and B2C marketing and distribution of its products. In terms of revenue generation, Paracetamol, Ibuprofen, Metformin, Methocarbamol, and Guaifenesin, which are five key products, contributed to 85 percent of the company’s FY2023 revenue.
Looking ahead, Granules India has outlined strategic initiatives to drive its future growth. The company is focused on strengthening its core API portfolio, which involves enhancing the quality and expanding the range of APIs it offers.
Additionally, Granules India aims to optimize its product mix, which may include developing new formulations or diversifying its product offerings to cater to evolving market demands.
Expanding its presence in more geographies is another key objective for Granules India. By entering new markets and forging strategic partnerships, the company aims to leverage its manufacturing capabilities and product portfolio to capture a wider customer base.
Considering these growth prospects, domestic brokerage firm ICICI Securities has maintained a buy rating on Granules India. They have set a target price of Rs 360, indicating their positive outlook on the company’s future performance.
Overall, Granules India’s strategic focus on strengthening its core portfolio, diversifying its product mix, and expanding its presence in new markets positions the company for continued growth in the foreseeable future.
Disclaimer: The opinions or perspectives shared on sharemarket.org.in are solely those of the individual expert or brokerage firm. The website or management holds no responsibility for the content. We strongly recommend users to seek certified expert advice before making any investment decisions.
